Golden
Orbit Discovery

Orbit Discovery

Orbit Discovery offers a DNA-encoded peptide display technology to identify potential peptide drugs for a range of chronic diseases.

Orbit Discovery Ltd. is a biotechnology company headquartered in Oxfordshire, United Kingdom and was founded in 2015 by Graham Ogg and Terry Rabbitts.



The company offers a DNA-encoded peptide display technology which was developed at the Weatherall Institute of Molecular Medicine. Peptides are biological molecules that like proteins are made up of amino acids, but peptides are smaller, consisting of 2-50 amino acids.



The in vitro display technology links randomized peptide sequences to small beads along with the DNA that encodes them. A DNA library is constructed coding for a scaffold and random or semi-randomised peptide sequence. After in vitro transcription and translation, each bead in the library displays several thousand copies of its specific peptide. Orbit technology can be used to screen for cell surface target binding.

Peptide display technology





Orbit's peptide display technology supports the presentation of natural amino acids, non-natural amino acids, linear peptides, constrained peptides and peptides modified after translation. The company's business model is to establish internal discovery programmes, which will be out-licensed, and collaborative programs with industry and academia.

Funding

Seed

On November 27, 2015 Orbit Discovery completed their seed funding round with £100 in funding from Oxford Technology Management. 

Series A

On May 23, 2018 Orbit Discovery closed a £6.9M Series A Financing. The round was led by Oxford Sciences Innovation, joined by new investors RT Ventures, Borealis Ventures, Perivoli Innovations, along with further investment from all existing investors and Oxford University, Borealis Managing Partner Phil Ferneau and Oxford Investment Consultants' Partner James Mallinson became Board of Directors at Orbit Discovery.

Timeline

March 29, 2019

Seed funding round

On November 27, 2015 Orbit Discovery completed their seed funding round with £100 in funding from Oxford Technology Management. 

May 23, 2018

Series A funding round

On May 23, 2018 Orbit Discovery closed a £6.9M Series A Financing. The round was led by Oxford Sciences Innovation, joined by new investors RT Ventures, Borealis Ventures, Perivoli Innovations, along with further investment from all existing investors and Oxford University, Borealis Managing Partner Phil Ferneau and Oxford Investment Consultants' Partner James Mallinson became Board of Directors at Orbit Discovery.

Funding rounds

1 Result
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Alex Batchelor

CEO



Graham Ogg

Co-founder



Terry Rabbitts

Co-founder



Further reading

Title
Author
Link
Type
Date

In vitro methods for peptide display and their applications

Christopher G. Ullman Laura Frigotto R. Neil Cooley





Peptide Display Company Orbit Discovery Closes £6.9M Series A Financing

B3C Newswire

Web



This Oxford Biotech is Using DNA to Find New Peptide Drugs

Alexander Burik

Web



Documentaries, videos and podcasts

Title
Date
Link

Orbit Discovery - DNA Encoded Peptide Display

October 25, 2018

ORBIT Peptide Display - High Throughout Selection of Peptides with Biological Function

Oct 20, 2017

Companies

Company
CEO
Location
Products/Services









References